Capricor DMD cell therapy data in The Lancet before FDA ruling
Capricor Therapeutics has announced that The Lancet has published peer-reviewed results from the HOPE-3 Phase 3 trial of deramiocel, its allogeneic cell therapy for Duchenne muscular dystrophy (DMD). The publication arrives less than four weeks before the FDA's PDUFA target action date of 22 August 2026, when the agency is expected to rule on the company's biologics licence application (BLA).
The randomised, double-blind, placebo-controlled trial enrolled 106 participants, predominantly non-ambulatory patients with advanced DMD. The study met its primary endpoint: deramiocel slowed decline in upper limb function, as measured by the Performance of Upper Limb 2.0 scale, by 54% versus placebo (p=0.03). The release also cited what it described as clinically meaningful improvements in several cardiac measures, though specific cardiac data points were not detailed in the announcement itself.
Trial significance
Craig McDonald, Distinguished Professor at UC Davis Health and the trial's national principal investigator, described the scale of benefit as "substantial" in a disease where functional decline is "typically relentless and irreversible." He noted that HOPE-3 is the first Phase 3 study to demonstrate a statistically significant functional benefit in a largely non-ambulatory DMD population, and that the concurrent cardiac findings lend biological support to a consistent treatment effect across both skeletal and cardiac muscle.
Linda Marbán, chief executive of Capricor, said the Lancet publication reinforces the company's confidence in the evidence base supporting the BLA. "Deramiocel can change the course of this disease," she said, "and we are focused on our goal of bringing it to patients as the first approved cell therapy for Duchenne."
Deramiocel holds a notable set of regulatory designations: Orphan Drug status from both the FDA and EMA, Regenerative Medicine Advanced Therapy (RMAT) designation, Advanced Therapy Medicinal Product (ATMP) classification in Europe, and Rare Pediatric Disease Designation, which could entitle Capricor to a Priority Review Voucher if approval is granted.
Competitive and regulatory context
DMD remains one of the most challenging areas in rare-disease drug development, and the competitive field has expanded considerably over the past decade. Sarepta Therapeutics holds the current approved cell and gene therapy in the space with its micro-dystrophin product Elevidys, which received accelerated approval in 2023 and full approval in 2024, making the comparative profile of deramiocel an important consideration for FDA reviewers. Deramiocel's mechanism is distinct: it works via allogeneic cardiosphere-derived cells that secrete exosomes, modulating macrophage behaviour to reduce inflammation and fibrosis rather than restoring dystrophin directly. If approved, it would be the first cell therapy cleared for DMD and would address a patient population, including older non-ambulatory patients, not well served by existing options.
The Lancet publication carries additional weight because independent peer review validates the statistical analysis plan and methodology, a point Capricor is likely to emphasise at its forthcoming Advisory Committee meeting. Investors will be watching closely: the 22 August PDUFA date makes this one of the more closely watched rare-disease regulatory decisions of 2026.